Fukunaka A, Fujitani Y
Early during treatment, gastrointestinal discomfort and enhanced satiety may reduce food appeal, whereas later stages may involve a more persistent reduction in motivation toward highly rewarding foods in some individuals
With the semaglutide patent in India set to expire soon, drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday (17) to comarket semaglutide injections, with a reusable pen device, in the country
The article says tapering is safer for people whose weight goals are achieved or stabilized, whose metabolic markers have improved, and whose lifestyle habits are established
Hormone replacement therapy has been shown to mitigate some of these immunological alterations
Individual response varies depending on medication, dosage, metabolism, and lifestyle habits